Venlafaxine Hydrochloride Tablet, Extended Release
Product Images NDC 72865-199

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Venlafaxine Hydrochloride (NDC 72865-199). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Xlcare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

150 mg 30ct

The label for Venlafaxine Extended-Release Tablets 150 mg by XLCare Pharmaceuticals, Inc. It shows the product name, strength, and dosage form with a quantity of 30 tablets. The label includes storage instructions, manufacturer information, and dispensing notes. A barcode and lot/expiration fields are also visible.*

FDA Label Image

150 mg 90ct

Label for Venlafaxine Extended-Release Tablets 150 mg by XLCare Pharmaceuticals, Inc. The label indicates the product contains 90 tablets and is for prescription use only. The label includes storage instructions, manufacturer and labeler details, dosage form, and a note to dispense with the attached Medication Guide.*

FDA Label Image

225 mg 30ct

Label of VENLAFAXINE HYDROCHLORIDE extended-release oral tablets, 225 mg strength, from XLCare Pharmaceuticals, Inc. The label shows the product name, dosage strength, quantity of 30 tablets, and includes manufacturer and storage guidance details. It is marked Rx only with barcode and lot information section visible.*

FDA Label Image

225 mg 90ct

Packaging label for Venlafaxine Extended-Release Tablets 225 mg by XLCare Pharmaceuticals, Inc. The label includes the NDC 72865-200-90 and states the package contains 90 tablets. It provides storage instructions, manufacturer information, and a note to authorized dispensers regarding the medication guide.*

FDA Label Image

37.5 mg 30 Ct

Label for Venlafaxine Extended-Release Tablets 37.5 mg by XLCare Pharmaceuticals, Inc. Oral tablets, extended release, in a package of 30 tablets. The label includes dosing information, storage instructions, and manufacturer details for Ascent Pharmaceuticals, Inc. and XLCare Pharmaceuticals, Inc.*

FDA Label Image

37.5 mg 90ct

Label for Venlafaxine Extended-Release Tablets, 37.5 mg strength, oral dosage form. The label indicates 90 tablets per package and is for prescription use only. It includes storage instructions, manufacturer and labeler information: manufactured by Ascent Pharmaceuticals, Inc. and labeled by XLCare Pharmaceuticals, Inc. The label features the NDC 72865-197-90 and specifies it is for extended-release venlafaxine hydrochloride tablets.*

FDA Label Image

75 mg 30ct

Label for Venlafaxine Extended-Release Tablets 75 mg by XLCare Pharmaceuticals, Inc. The package contains 30 oral extended-release tablets. It includes storage instructions, dosage form, strength, manufacturer information, and a note to authorized dispensers to provide the medication guide with each dispensing.*

FDA Label Image

75 mg 90ct

Label for Venlafaxine Extended-Release Tablets 75 mg oral tablets by XLCare Pharmaceuticals, Inc., NDC 72865-198-90. The package contains 90 tablets. The label includes storage instructions, dosage note, manufacturer and labeler information.*

FDA Label Image

Symptoms Med Guide

A partial text panel listing behavioral and mood-related warning signs, including thoughts about suicide, worsening depression or anxiety, increased agitation, panic attacks, insomnia, irritability, aggression, dangerous impulses, mania, unusual mood changes, and visual problems such as eye pain or swelling.*

FDA Label Image

Tab-1 (Tab 1)

A table presenting the drug-placebo difference in number of cases of suicidality per 1000 patients treated with venlafaxine hydrochloride by age range. It shows increased cases compared to placebo for patients under 18 and ages 18-24, and decreased cases for ages 25-64 and 65 or older.*

FDA Label Image

Tab 2 And 3

Two tables presenting data on systolic diastolic blood pressure (SDBP) elevations related to Venlafaxine Hydrochloride. Table 2 shows the number and percentage of sustained SDBP elevations in extended-release capsule premarketing studies by indication (Major Depressive Disorder and other clinical trials). Table 3 shows the incidence percentages of sustained SDBP elevations in immediate-release tablet studies categorized by Venlafaxine daily dose ranges.*

FDA Label Image

Tab-4 (Tab 4)

A data table titled 'Final On-Therapy Mean Changes from Baseline in Supine Systolic and Diastolic Blood Pressure (mm Hg) Results by Indication, Study Duration, and Dose in Placebo-Controlled Trials.' It compares changes in supine systolic and diastolic blood pressure for venlafaxine hydrochloride extended-release capsules at doses ≤75 mg/day and >75 mg/day versus placebo, across indications Major Depressive Disorder (8-12 weeks) and Other Clinical Trials (12 weeks).*

FDA Label Image

Tab-5 (Tab 5)

A table showing the incidence of insomnia and nervousness in placebo-controlled trials for Major Depressive Disorder and other trials. It compares rates between venlafaxine hydrochloride extended-release capsules and placebo groups, with sample sizes and reported percentages for each symptom.*

FDA Label Image

Struct

Chemical structure of venlafaxine hydrochloride, showing its molecular framework with aromatic and cyclic components, hydroxyl group, and hydrochloride (HCl) salt representation.*

FDA Label Image

Tab 6

A data table titled 'Table 6 Treatment-Emergent Adverse Reaction Incidence in Short-Term Placebo-Controlled Clinical Trials with Venlafaxine Hydrochloride Extended-Release Capsules in Patients with Major Depressive Disorder.' It lists the percentage reporting of various adverse reactions by body system, comparing Venlafaxine Hydrochloride Extended-Release Capsules (n=357) to placebo (n=285). Reactions include those affecting the body as a whole, cardiovascular, digestive, metabolic/nutritional, nervous, respiratory, skin, special senses, and urogenital systems.*

FDA Label Image

Tab 7

A data table showing the incidence of treatment-emergent adverse reactions in short-term placebo-controlled clinical trials of Venlafaxine Hydrochloride Extended-Release Capsules compared to placebo. The table details adverse reactions by body system and preferred term with corresponding percentages in venlafaxine and placebo groups among social anxiety disorder patients.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.